Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Eli Lilly's acquisition of Verve Therapeutics for $1.3 billion has sparked interest in the gene editing space, with analysts speculating on potential market boosts. Recent M&A activity in the biopharma sector has accelerated, despite challenges from drug pricing policies and tariff threats. In other news, a court order has restored canceled NIH grants, and a CDC scientist has resigned over vaccine regulation concerns. Updates on various biotech developments, including Intellia Therapeutics' aim to develop genome editing treatments for severe diseases, are also making headlines.Stay tuned for more updates on the latest developments in the pharmaceutical industry.

Support the show